淋巴毒素β受体在固体瘤免疫力和治疗向中的多细胞和多细胞作用
Anshu1, Nair Shantikumar V1, Roy Sreeja1
1Amrita Research Center Delhi NCR, Amrita Vishwa Vidyapeetham Faridabad, Faridabad, Haryana, India.
Frontiers in immunology
|February 20, 2026
概括
淋巴毒素β受体 (LTβR) 显示在癌症免疫中具有双重作用. 战略性LTβR激活可以重新编程瘤微环境,提高免疫治疗对PDAC,GBM和TNBC等固体瘤的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 免疫疗法已经彻底改变了癌症治疗,但在PDAC,GBM和TNBC等固体瘤中面临阻力.
- 这种抗性与免疫透不良和免疫抑制性瘤微环境 (TMEs) 有关.
- 淋巴毒素β受体 (LTβR) 是TME调节的关键参与者,其影响取决于上下文.
研究的目的:
- 检查LTβR在固体瘤中的双重功能作用.
- 探索LTβR调制在克服免疫疗法耐药性的治疗潜力.
- 研究LTβR与免疫细胞的相互作用以及与其他疗法的协同作用.
主要方法:
- 对各种癌症中LTβR信号传递的临床前和临床数据的审查.
- 分析LTβR对TME组件,如三级淋巴细胞结构 (TLS) 和免疫细胞的影响.
- 探索LTβR的激进和对抗策略.
主要成果:
- 激活LTβR可以通过诱导TLS,高内皮静脉 (HEV) 和免疫透来促进抗瘤免疫.
- 相反,持久的LTβR信号可以支持免疫抑制表型和瘤生长.
- LTβR调制显示出与免疫检查点阻断 (ICB) 和CAR T细胞疗法的潜在协同作用.
结论:
- 战略性LTβR刺激提供了一种有希望的方法来重编程TME并增强抗瘤免疫力.
- 向LTβR可能会在耐火固体瘤中克服对当前免疫疗法的耐药性.
- 选择性LTβR调制可以在具有挑战性的癌症中扩大持久反应.
关键词:
抗瘤免疫和免疫治疗的免疫力.淋巴毒素β受体的受体为淋巴毒素β.淋巴毒素ββ受体的类受体.骨髓质细胞重编程可以实现.基于非T细胞的免疫疗法.新的免疫治疗方法.固体瘤免疫力 固体瘤免疫力固体瘤微环境是一个微环境.更多相关视频
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.9K
07:45Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
Published on: January 26, 2024
2.9K
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Receptor Downregulation in MVBs
2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.9K
